Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 1.9% - What's Next?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s stock price shot up 1.9% on Thursday . The company traded as high as $7.39 and last traded at $7.38. 4,449,983 shares were traded during trading, a decline of 35% from the average session volume of 6,807,676 shares. The stock had previously closed at $7.24.

Analyst Ratings Changes

A number of research firms recently commented on RXRX. Jefferies Financial Group decreased their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating on the stock in a report on Tuesday, September 3rd. Leerink Partners dropped their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating for the company in a research note on Tuesday, September 3rd. Finally, Needham & Company LLC reissued a "buy" rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $9.25.

Recursion Pharmaceuticals Trading Up 5.8 %

The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $2.20 billion, a PE ratio of -5.01 and a beta of 0.85. The business's fifty day moving average price is $6.80 and its 200 day moving average price is $7.16.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.01). The company had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm's quarterly revenue was up 147.6% on a year-over-year basis. During the same quarter last year, the firm posted ($0.43) EPS. As a group, analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Insider Transactions at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $6.22, for a total value of $71,200.34. Following the completion of the sale, the director now owns 7,098,428 shares in the company, valued at $44,152,222.16. This represents a 0.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Christopher Gibson sold 20,000 shares of Recursion Pharmaceuticals stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $6.16, for a total value of $123,200.00. Following the sale, the chief executive officer now directly owns 762,656 shares of the company's stock, valued at approximately $4,697,960.96. The trade was a 2.56 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 101,788 shares of company stock worth $682,691. Company insiders own 15.75% of the company's stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several institutional investors have recently made changes to their positions in RXRX. Axxcess Wealth Management LLC lifted its holdings in Recursion Pharmaceuticals by 4.3% in the 3rd quarter. Axxcess Wealth Management LLC now owns 43,884 shares of the company's stock worth $289,000 after purchasing an additional 1,795 shares during the last quarter. Green Alpha Advisors LLC raised its holdings in shares of Recursion Pharmaceuticals by 2.9% in the 3rd quarter. Green Alpha Advisors LLC now owns 64,799 shares of the company's stock worth $427,000 after buying an additional 1,800 shares in the last quarter. Interchange Capital Partners LLC boosted its holdings in shares of Recursion Pharmaceuticals by 7.3% in the 2nd quarter. Interchange Capital Partners LLC now owns 34,580 shares of the company's stock worth $268,000 after acquiring an additional 2,349 shares in the last quarter. Amalgamated Bank increased its stake in shares of Recursion Pharmaceuticals by 52.4% in the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company's stock valued at $54,000 after buying an additional 2,459 shares during the period. Finally, Victory Capital Management Inc. lifted its holdings in Recursion Pharmaceuticals by 13.5% in the second quarter. Victory Capital Management Inc. now owns 21,891 shares of the company's stock valued at $164,000 after buying an additional 2,598 shares during the period. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.